MediSix Therapeutics Pte Ltd. logo

MediSix Therapeutics Pte Ltd.

Medisix is an Immune Engineering CAR-T company targeting T-Cell malignancies 2017 MediSix Therapeutics is a development-stage immune engineering company developing novel chimeric antigen receptor (_CAR”) T cells to target T-cell leukemia and lymphoma.

MediSix Therapeutics was founded by Professor Dario Campana, MD, PhD, of the Department of Pediatrics, National University of Singapore (NUS) Yong Loo Lin School of Medicine, and Lighstone Singapore Pte. Ltd. MediSix has an exclusive licensing agreement with NUS, enabling it to develop breakthrough treatments for T-cell blood cancers, an area where effective immunotherapies are currently lacking.

0
Management
0
Technology
0
Deals/Partnering
0
Research Pipeline
0
Funding
BioStartup's Score 0 / 50

KEY DETAILS

Websitehttp://medisixtx.com
Founded2017
Disease Focus
Development Stage
STOCK CODENon Listed
Address
30 Cecil Street No 19-08 Prudential Tower,049712
Singapore
Singapore
Email
Contact Number

[atom_linkedin linkedin_option=”CompanyInsider” linkedin_id=”https://www.linkedin.com/company/medisix-therapeutics-pte-ltd” connections=”true” suffix=””]

In May 2018, MediSix raised $20Mn in Series A financing, led by Lightstone Ventures, with participation from Temasek and Osage University Partners. The funds will be used to advance product development and initiate early pre-clinical studies.